Paper Details

  1. Home
  2. Paper Details

Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia.

Author: AbrahamIvo, AlrawashdhNeda, ErstadBrian, McBrideAli, PerskyDaniel O, SweasyJoann

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This study estimated the 10-year cost-effectiveness of various treatment regimens for chronic lymphocytic leukemia.
Paper Details　
Original Abstract of the Article :
Several chemoimmunotherapy and targeted treatment regimens are approved as front-line therapies in chronic lymphocytic leukemia. We estimated for the 10-year cost-effectiveness of these treatment regimens and the economic burden of following the estimated risk-stratified 21 040 patients with chronic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jval.2022.04.001

データ提供：米国国立医学図書館（NLM）

Chronic Lymphocytic Leukemia: A Cost-Effective Approach to Treatment

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that requires careful management and treatment. This study investigates the cost-effectiveness of various first-line treatment regimens for CLL, aiming to optimize treatment strategies while considering both clinical efficacy and economic factors.

The researchers analyzed the cost-effectiveness of multiple chemoimmunotherapy and targeted treatment regimens for CLL, considering a 10-year time horizon. They also estimated the economic burden of treating an estimated 21,040 patients diagnosed with CLL in 2020 over a 10-year period. The study identified cost-effective treatment strategies based on risk stratification, aiming to provide valuable insights for clinicians and healthcare decision-makers.

Balancing Clinical Benefits and Costs in CLL Treatment

The study highlights the importance of considering cost-effectiveness when making treatment decisions for CLL patients. The authors emphasize the need for a balanced approach that ensures optimal clinical outcomes while minimizing financial burden. The findings provide valuable data to support evidence-based decisions in CLL management.

Managing CLL: A Collaborative Journey

The study underscores the importance of collaborative efforts between clinicians, healthcare systems, and patients in managing CLL. The need for cost-effective treatment strategies highlights the importance of open communication and shared decision-making to ensure that patients receive the best possible care while considering both clinical and financial factors.

Dr. Camel's Conclusion

The desert of CLL treatment is vast and complex, with numerous treatment options and considerations. This study provides a valuable roadmap for navigating this terrain, emphasizing the need for cost-effective strategies that optimize both clinical outcomes and financial resources. By understanding the economic implications of treatment choices, we can work together to ensure that CLL patients receive the best possible care, guided by a blend of scientific evidence and financial prudence.

Date :
  1. Date Completed 2022-10-18
  2. Date Revised 2022-11-16
Further Info :

Pubmed ID

35537984

DOI: Digital Object Identifier

10.1016/j.jval.2022.04.001

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.